Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients

Seminars in Dialysis

Volumn 25, Issue 5, 2012, Pages 529-538

  Mallipattu, Sandeep K ^a   He, John C ^a,b   Uribarri, Jaime ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ANIMAL; ARTICLE; ARTIFICIAL MEMBRANE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COOKING; DIABETES MELLITUS; DISEASE MODEL; HUMAN; METABOLISM; RENAL REPLACEMENT THERAPY;

ANIMALS; CARDIOVASCULAR DISEASES; COOKING; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; RENAL DIALYSIS;

EID: 84866549194     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2012.01081.x     Document Type: Article

References (146)

1. Maillard LC: The action of amino acids on sugar; The formation of melanoidin by a methodic route. Cr Hebd Acad Sci 154:66-68, 1912
2. Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD: Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 10:657-664, 1995
3. Bucala R, Cerami A: Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23:1-34, 1992
4. Munch G, Gerlach M, Sian J, Wong A, Riederer P: Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol 44:S85-S88, 1998
5. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, Saito A, Kurokawa K, van Ypersele de Strihou C: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
6. Thorpe SR, Baynes JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9:69-77, 1996
7. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 93:2353-2358, 1996
8. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 264:21597-21602, 1989
9. Ahmed MU, Thorpe SR, Baynes JW: Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261:4889-4894, 1986
10. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, Litchfield JE, Ahmed MU, Reddy S, Zyzak DV, Thorpe SR, Baynes JW: New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 11(Suppl. 5):41-47, 1996
11. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94:6474-6479, 1997
12. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H: Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 8:337-346, 2002
13. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A: Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 94:13915-13920, 1997
14. Vlassara H, Uribarri J, Cai W, Striker G: Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci 1126:46-52, 2008
15. Yan SF, Ramasamy R, Schmidt AM: The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med 11:e9, 2009
16. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4:285-293, 2008
17. Cai W, He JC, Zhu L, Lu C, Vlassara H: Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 103:13801-13806, 2006
18. Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H: AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 294:C145-C152, 2008
19. He CJ, Koschinsky T, Buenting C, Vlassara H: Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 7:159-168, 2001
20. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. QJM 87:679-683, 1994
21. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
22. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E: Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 14:1968-1975, 1999
23. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, Van Ypersele De Strihou C, Miyata T: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress". Kidney Int 55:2487-2492, 1999
24. Schinzel R, Munch G, Heidland A, Sebekova K: Advanced glycation end products in end-stage renal disease and their removal. Nephron 87:295-303, 2001
25. Vlassara H: Serum advanced glycosylation end products: a new class of uremic toxins? Blood Purif 12:54-59, 1994
26. Kalousova M, Skrha J, Zima T: Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51:597-604, 2002
27. Fagugli RM, Vanholder R, De Smet R, Selvi A, Antolini F, Lameire N, Floridi A, Buoncristiani U: Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int J Artif Organs 24:256-262, 2001
28. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 17:1045-1049, 2002
29. Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW: Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis 42:524-531, 2003
30. Lamb E, Cattell WR, Dawnay A: Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Sci (Lond) 84:619-626, 1993
31. Lamb EJ, Cattell WR, Dawnay AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 47:1768-1774, 1995
32. Ateshkadi A, Johnson CA, Founds HW, Zimmerman SW: Serum advanced glycosylation end-products in patients on hemodialysis and CAPD. Perit Dial Int 15:129-133, 1995
33. Mahiout A, Ehlerding G, Brunkhorst R: Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients. Nephrol Dial Transplant 11(Suppl. 5):2-6, 1996
34. Yamada K, Miyahara Y, Hamaguchi K, Nakayama M, Nakano H, Nozaki O, Miura Y, Suzuki S, Tuchida H, Mimura N: Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 42:354-361, 1994
35. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 51:182-186, 1997
36. Dawnay AB, Millar DJ: Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 17:52-58, 1997
37. Ho-dac-Pannekeet MM, Weiss MF, de Waart DR, Erhard P, Hiralall JK, Krediet RT: Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions. Perit Dial Int 19(Suppl. 2):S68-S74, 1999
38. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 14:1541-1549, 1999
39. Linden T, Forsback G, Deppisch R, Henle T, Wieslander A: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 18:290-293, 1998
40. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T: Induction of 1, 2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 19:325-333, 1999
41. Wieslander A, Linden T, Musi B, Jarkelid L, Speidel R, Beck W, Henle T, Deppisch R: Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids. Contrib Nephrol 131:82-89, 2001
42. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298-305, 2003
43. Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, Pischetsrieder M: Formation of advanced glycation end products during CAPD. Am J Kidney Dis 41:S57-S60, 2003
44. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE: Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 25:445-451, 1995
45. Friedlander MA, Wu YC, Elgawish A, Monnier VM: Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest 97:728-735, 1996
46. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C: Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51:880-887, 1997
47. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14:728-731, 2003
48. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
49. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46:216-222, 1994
50. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 35:365-380, 2000
51. Schwedler S, Schinzel R, Vaith P, Wanner C: Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl 78:S32-S36, 2001
52. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 44:129-146, 2001
53. Kalousova M, Zima T, Tesar V, Stipek S, Sulkova S: Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 27:18-28, 2004
54. Bohlender JM, Franke S, Stein G, Wolf G: Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289:F645-F659, 2005
55. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, Paroni R, Malatino LS: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 18:1207-1213, 2000
56. Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, Memmos D: Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 18:113-119, 2003
57. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
58. Vlassara H: Recent progress in advanced glycation end products and diabetic complications. Diabetes 46(Suppl. 2):S19-S25, 1997
59. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP: AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37:586-600, 1998
60. Gascho JA, Fanelli C, Zelis R: Aging reduces venous distensibility and the venodilatory response to nitroglycerin in normal subjects. Am J Cardiol 63:1267-1270, 1989
61. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432-438, 1991
62. Taki K, Takayama F, Tsuruta Y, Niwa T: Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 70:218-224, 2006
63. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F: Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 105:2632-2637, 2002
64. Witztum JL: The role of oxidized LDL in atherosclerosis. Adv Exp Med Biol 285:353-365, 1991
65. Menzel EJ, Sobal G, Staudinger A: The role of oxidative stress in the long-term glycation of LDL. Biofactors 6:111-124, 1997
66. Wagner Z, Molnar M, Molnar GA, Tamasko M, Laczy B, Wagner L, Csiky B, Heidland A, Nagy J, Wittmann I: Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 47:294-300, 2006
67. Zhou Y, Yu Z, Jia H, Sun F, Ma L, Guo R, Peng L, Cui T: Association of serum pentosidine with arterial stiffness in hemodialysis patients. Artif Organs 34:193-199, 2010
68. Tanaka K, Katoh T, Asai J, Nemoto F, Suzuki H, Asahi K, Sato K, Sakaue M, Miyata T, Watanabe T: Relationship of skin autofluorescence to cardiovascular disease in Japanese hemodialysis patients. Ther Apher Dial 14:334-340, 2010
69. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16:3687-3693, 2005
70. Nagano M, Fukami K, Yamagishi S, Sakai K, Kaida Y, Matsumoto T, Hazama T, Tanaka M, Ueda S, Okuda S: Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology (Carlton) 16:299-303, 2011
71. Wrobel K, Garay-Sevilla ME, Nava LE, Malacara JM: Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 43:1563-1569, 1997
72. Roberts MA, Thomas MC, Fernando D, Macmillan N, Power DA, Ierino FL: Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 21:1611-1617, 2006
73. Kalousova M, Jachymova M, Germanova A, Kubena AA, Tesar V, Zima T: Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. Kidney Blood Press Res 33:30-36, 2010
74. Schwedler SB, Metzger T, Schinzel R, Wanner C: Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62:301-310, 2002
75. Sebekova K, Podracka L, Heidland A, Schinzel R: Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation - are they inter-related? Clin Nephrol 56:S21-S26, 2001
76. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS: Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65:1492-1498, 2004
77. Stein G, Busch M, Muller A, Wendt T, Franke C, Niwa T, Franke S: Are advanced glycation end products cardiovascular risk factors in patients with CRF? Am J Kidney Dis 41:S52-S56, 2003
78. Descamps-Latscha B, Jungers P, Witko-Sarsat V: Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 20:481-484, 2002
79. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, Halperin J: Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 97:5450-5455, 2000
80. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int Suppl 78:S271-S277, 2001
81. Fujimoto N, Tajima S: Advanced glycation end product (AGE)-immunoreactive materials in chronic prurigo patients receiving a long-standing haemodialysis. Br J Dermatol 150:757-760, 2004
82. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T: beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
83. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H: Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 93:521-528, 1994
84. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, Schmidt AM: The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98:1088-1094, 1996
85. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12:255-258, 1997
86. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y: Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 49:861-867, 1996
87. Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y: Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 51:187-194, 1997
88. Hou FF, Chertow GM, Kay J, Boyce J, Lazarus JM, Braatz JA, Owen WF Jr: Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int 51:1514-1519, 1997
89. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H: Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 18:224-237, 2002
90. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99:15596-15601, 2002
91. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE, Uribarri J: Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94:4483-4491, 2009
92. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34:1610-1616, 2011
93. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104:1287-1291, 2004
94. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H: Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110:911-916.e12, 2010
95. Piroddi M, Palazzetti I, Quintaliani G, Pilolli F, Montaldi M, Valentina V, Libetta C, Galli F: Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study. J Ren Nutr 21:329-339, 2011
96. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149:820-825, 2005
97. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA: Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3:1125-1130, 2008
98. Shantouf R, Budoff MJ, Ahmadi N, Tiano J, Flores F, Kalantar-Zadeh K: Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 28:275-279, 2008
99. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A: Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57:422-431, 2011
100. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker G: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. (7) Published ahead of print, 2012. DOI: 10.2215.
101. Shimizu H, Okada S, Shinsuke OI, Mori M: Kremezin (AST-120) delays the progression of diabetic nephropathy in Japanese type 2 diabetic patients. Diabetes Care 28:2590, 2005
102. Ueda S, Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda S: Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 12:180-184, 2006
103. Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T: Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl 63:S188-S190, 1997
104. Shoji T, Wada A, Inoue K, Hayashi D, Tomida K, Furumatsu Y, Kaneko T, Okada N, Fukuhara Y, Imai E, Tsubakihara Y: Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 105:c99-c107, 2007
105. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y: AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 30:856-860, 2008
106. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y: AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 11:189-195, 2007
107. Jolles P: A possible physiological function of lysozyme. Biomedicine 25:275-276, 1976
108. Mitsuhashi T, Li YM, Fishbane S, Vlassara H: Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. J Clin Invest 100:847-854, 1997
109. Zheng F, Cai W, Mitsuhashi T, Vlassara H: Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy? Mol Med 7:737-747, 2001
110. Cocchietto M, Zorzin L, Toffoli B, Candido R, Fabris B, Stebel M, Sava G: Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy. Diabetes Metab 34:587-594, 2008
111. Zavaleta N, Figueroa D, Rivera J, Sanchez J, Alfaro S, Lonnerdal B: Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea. J Pediatr Gastroenterol Nutr 44:258-264, 2007
112. Miyata T, Ueda Y, Asahi K, Izuhara Y, Inagi R, Saito A, Van Ypersele De Strihou C, Kurokawa K: Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11:1719-1725, 2000
113. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, Geyer J, Kopcke W, Sauerland C, Bretzel RG, Federlin KF: Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 109:330-336, 2001
114. Kihm LP, Muller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, Adaikalakoteswari A, Thornalley PJ, Hammes HP, Nawroth PP, Zeier M, Schwenger V: Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 22:914-926, 2011
115. Schupp N, Dette EM, Schmid U, Bahner U, Winkler M, Heidland A, Stopper H: Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol 378:283-291, 2008
116. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJ: A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33:1598-1601, 2010
117. Nascimento MM, Suliman ME, Murayama Y, Nihi M, Hayashi SY, Stenvinkel P, Riella MC, Lindholm B: Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study. J Ren Nutr 16:119-124, 2006
118. Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 93:3902-3907, 1996
119. Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, Park MS: Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int 21:245-253, 2001
120. Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, Schadee-Eestermans IL, Schalkwijk CG, Beelen RH, van den Born J: Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant 20:2783-2792, 2005
121. Nilsson BO: Biological effects of aminoguanidine: an update. Inflamm Res 48:509-515, 1999
122. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32-40, 2004
123. Miyata T, Ishikawa S, Asahi K, Inagi R, Suzuki D, Horie K, Tatsumi K, Kurokawa K: 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445:202-206, 1999
124. Khalifah RG, Baynes JW, Hudson BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257:251-258, 1999
125. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63:2123-2133, 2003
126. Mizuiri S, Ohashi Y, Hemmi H, Arita M, Yamada K, Aoki T, Miyagi M, Sakai K, Aikawa A: Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGF-beta1 and VEGF expression in rat peritoneal mesothelial cells. Am J Nephrol 30:295-302, 2009
127. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478-2487, 2002
128. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A: Advanced glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 25:380-383, 1999
129. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LM, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274-3282, 2002
130. Sebekova K, Lill M, Boor P, Heidland A, Amann K: Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system. Am J Nephrol 29:164-170, 2009
131. Li C, Yang CW, Park CW, Ahn HJ, Kim WY, Yoon KH, Suh SH, Lim SW, Cha JH, Kim YS, Kim J, Chang YS, Bang BK: Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats. Kidney Int 63:454-463, 2003
132. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K: Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14:1212-1222, 2003
133. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL: Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 301:65-77, 2000
134. Kanazawa I, Yamamoto M, Yamaguchi T, Sugimoto T: Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 119:362-365, 2011
135. Baragetti I, Furiani S, Vettoretti S, Raselli S, Maggi FM, Galli F, Catapano AL, Buccianti G: Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. Blood Purif 24:369-376, 2006
136. Erixon M, Linden T, Kjellstrand P, Carlsson O, Ernebrant M, Forsback G, Wieslander A, Jonsson JA: PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization. Perit Dial Int 24:392-398, 2004
137. Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, Izuhara Y, Saito A, Kurokawa K, Van Ypersele De Strihou C: Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 58:2518-2524, 2000
138. Posthuma N, Verbrugh HA, Donker AJ, van Dorp W, Dekker HA, Peers EM, Oe PL, ter Wee PM: Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int 20:174-180, 2000
139. Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, Schmidt AM: The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant 11(Suppl. 5):13-16, 1996
140. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95:4630-4634, 1998
141. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11:191-195, 2005
142. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464-1470, 2001
143. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA: Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 13:899-908, 2011
144. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97:238-243, 1996
145. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T: Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 14:487-495, 2008
146. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P, Heimburger O, Stenvinkel P, Lindholm B: Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 5:2213-2219, 2010